These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22890587)

  • 1. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study.
    Meek IL; Vonkeman HE; Kasemier J; Movig KL; van de Laar MA
    Eur J Clin Pharmacol; 2013 Mar; 69(3):365-71. PubMed ID: 22890587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.
    Angiolillo DJ; Hwang C; Datto C; Desai B; Sostek M
    Clin Ther; 2011 Dec; 33(12):1883-93. PubMed ID: 22078153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of common nonsteroidal anti-inflammatory medications by whole blood aggregometry: a clinical evaluation for the perioperative setting.
    Scott WW; Levy M; Rickert KL; Madden CJ; Beshay JE; Sarode R
    World Neurosurg; 2014 Nov; 82(5):e633-8. PubMed ID: 24698769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
    Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib.
    Bavbek S; Celik G; Ozer F; Mungan D; Misirligil Z
    J Asthma; 2004 Feb; 41(1):67-75. PubMed ID: 15046380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.
    Van Hecken A; Schwartz JI; Depré M; De Lepeleire I; Dallob A; Tanaka W; Wynants K; Buntinx A; Arnout J; Wong PH; Ebel DL; Gertz BJ; De Schepper PJ
    J Clin Pharmacol; 2000 Oct; 40(10):1109-20. PubMed ID: 11028250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials.
    Curtis SP; Ng J; Yu Q; Shingo S; Bergman G; McCormick CL; Reicin AS
    Clin Ther; 2004 Jan; 26(1):70-83. PubMed ID: 14996519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerance to COX-2 inhibitors in children with hypersensitivity to nonsteroidal anti-inflammatory drugs.
    Corzo JL; Zambonino MA; Muñoz C; Mayorga C; Requena G; Urda A; Gallego C; Blanca M; Torres MJ
    Br J Dermatol; 2014 Mar; 170(3):725-9. PubMed ID: 24116718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers.
    van Kraaij DJ; Hovestad-Witterland AH; de Metz M; Vollaard EJ
    Br J Clin Pharmacol; 2002 Jun; 53(6):644-7. PubMed ID: 12047490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis.
    Knijff-Dutmer EA; Kalsbeek-Batenburg EM; Koerts J; van de Laar MA
    Rheumatology (Oxford); 2002 Apr; 41(4):458-61. PubMed ID: 11961179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
    Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
    Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study.
    Bavbek S; Dursun AB; Dursun E; Eryilmaz A; Misirligil Z
    Int Arch Allergy Immunol; 2007; 142(1):64-9. PubMed ID: 17016059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meloxicam: selective COX-2 inhibition in clinical practice.
    Furst DE
    Semin Arthritis Rheum; 1997 Jun; 26(6 Suppl 1):21-7. PubMed ID: 9219316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of meloxicam on platelet function in healthy adults: a randomized, double-blind, placebo-controlled trial.
    Rinder HM; Tracey JB; Souhrada M; Wang C; Gagnier RP; Wood CC
    J Clin Pharmacol; 2002 Aug; 42(8):881-6. PubMed ID: 12162470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.
    Mendell J; Lee F; Chen S; Worland V; Shi M; Samama MM
    J Cardiovasc Pharmacol; 2013 Aug; 62(2):212-21. PubMed ID: 23615159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastric and renal effects of COX-2 selective and non-selective NSAIDs in rats receiving low-dose aspirin therapy.
    Moro MG; Sanchez PK; Gevert MV; Baller EM; Tostes AF; Lupepsa AC; Baglie S; Franco GC
    Braz Oral Res; 2016 Nov; 30(1):e127. PubMed ID: 27901208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of etoricoxib, a novel, selective COX-2 inhibitor.
    Dallob A; Hawkey CJ; Greenberg H; Wight N; De Schepper P; Waldman S; Wong P; DeTora L; Gertz B; Agrawal N; Wagner J; Gottesdiener K
    J Clin Pharmacol; 2003 Jun; 43(6):573-85. PubMed ID: 12817520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
    Watson DJ; Bolognese JA; Yu C; Krupa D; Curtis S
    Curr Med Res Opin; 2004 Dec; 20(12):1899-908. PubMed ID: 15701208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.